Moncef Slaoui, the head of the United States government's effort to develop a vaccine against Covid-19, said the first Americans to receive a vaccine - if all things go according to plan - could be as early as the second week of December.
Slaoui told CNN he expects vaccinations would begin on the second day after approval, December 12.
The US-based pharma giant will charge governments between $25 and $37 per dose of its COVID-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly Welt am Sonntag (WamS).
The price per dose of the Russian coronavirus vaccine Sputnik V will be much lower than that of the vaccines of USA drug giants Pfizer and Moderna, said the Russian vaccine's official Twitter account on Sunday. "Moderna had earlier stated that its vaccine might be priced between $25 and $37 per dose".
The statement comes shortly after U.S. pharmaceutical company Moderna announced that it would charge countries that want to buy its candidate vaccine against COVID-19 between $25 and $37 per dose.
A spokesperson for the Russian Direct Investment Fund (RDIF), which is investing in the production and promotion of the vaccine overseas, said that the price of Sputnik V would be unveiled next week. "The price of Sputnik V will be much lower", the official account said.
On 11 August, Russia became the first country in the world to register a coronavirus vaccine, dubbed Sputnik V. The vaccine, which is based on a human adenoviral vector platform, was developed by the Gamaleya Research Institute of Epidemiology and Microbiology and is now completing phase 3 clinical trials.
The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic.